BR112018004242A2 - composições de vacina que possuem estabilidade e imunogenicidade aumentadas - Google Patents
composições de vacina que possuem estabilidade e imunogenicidade aumentadasInfo
- Publication number
- BR112018004242A2 BR112018004242A2 BR112018004242A BR112018004242A BR112018004242A2 BR 112018004242 A2 BR112018004242 A2 BR 112018004242A2 BR 112018004242 A BR112018004242 A BR 112018004242A BR 112018004242 A BR112018004242 A BR 112018004242A BR 112018004242 A2 BR112018004242 A2 BR 112018004242A2
- Authority
- BR
- Brazil
- Prior art keywords
- increased stability
- immunogenicity
- vaccine compositions
- nanoparticles
- vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
são reveladas nesse relatório descritivo nanopartículas adequadas para uso em vacinas. as nanopartículas apresentam antígenos de patógenos circundados e associados com um núcleo de detergente, resultando em estabilidade aumentada e boa imunogenicidade. dosagens, formulações e métodos para a preparação das vacinas e nanopartículas também são revelados.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562213947P | 2015-09-03 | 2015-09-03 | |
US201562255786P | 2015-11-16 | 2015-11-16 | |
US201662309216P | 2016-03-16 | 2016-03-16 | |
US201662350973P | 2016-06-16 | 2016-06-16 | |
PCT/US2016/050413 WO2017041100A2 (en) | 2015-09-03 | 2016-09-06 | Vaccine compositions having improved stability and immunogenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018004242A2 true BR112018004242A2 (pt) | 2018-09-25 |
Family
ID=58188609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018004242A BR112018004242A2 (pt) | 2015-09-03 | 2016-09-06 | composições de vacina que possuem estabilidade e imunogenicidade aumentadas |
Country Status (14)
Country | Link |
---|---|
US (4) | US10426829B2 (pt) |
EP (1) | EP3344291A4 (pt) |
JP (4) | JP6670374B2 (pt) |
KR (1) | KR20180052124A (pt) |
CN (4) | CN108697790B (pt) |
AU (2) | AU2016315478B2 (pt) |
BR (1) | BR112018004242A2 (pt) |
CA (1) | CA2996007A1 (pt) |
HK (1) | HK1250136A1 (pt) |
IL (2) | IL257800B2 (pt) |
MX (3) | MX2018002728A (pt) |
RU (1) | RU2730625C2 (pt) |
SG (1) | SG10201913145SA (pt) |
WO (1) | WO2017041100A2 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011006205A (es) | 2008-12-09 | 2011-09-01 | Novavax Inc | Proteinas f del vrs modificadas y metodos de uso de las mismas. |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
IL257800B2 (en) | 2015-09-03 | 2023-11-01 | Novavax Inc | Immune compositions with improved stability and immunogenicity |
ES2922081T3 (es) | 2015-11-01 | 2022-09-07 | Glycobac Llc | Líneas celulares libres de virus y métodos para su obtención |
AU2018249533C1 (en) | 2017-04-04 | 2023-10-12 | Institute For Research In Biomedicine | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
JP7317796B2 (ja) * | 2017-07-24 | 2023-07-31 | ノババックス,インコーポレイテッド | 呼吸器疾患を治療するための方法および組成物 |
CN112088014A (zh) | 2018-02-28 | 2020-12-15 | 华盛顿大学 | 自组装纳米结构疫苗 |
IL305911A (en) * | 2018-03-19 | 2023-11-01 | Novavax Inc | Multifunctional nanoparticle vaccines for influenza |
WO2020123747A1 (en) * | 2018-12-14 | 2020-06-18 | Walmart Apollo, Llc | Automated bakery kiosk with order customization |
CN113365653A (zh) * | 2019-01-18 | 2021-09-07 | 佐治亚大学研究基金会股份有限公司 | 盐纳米颗粒和组合物及其使用方法 |
EP3930750A4 (en) * | 2019-02-28 | 2023-01-18 | Novavax, Inc. | METHODS OF PREVENTING AN ILLNESS OR DISORDER CAUSED BY RSV INFECTION |
IL295142A (en) * | 2020-01-27 | 2022-09-01 | Novavax Inc | Formulations for the vaccine against the corona virus |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
US20210317170A1 (en) * | 2020-04-14 | 2021-10-14 | Ut-Battelle, Llc | Compositions and methods for drug delivery and treating viral infections |
WO2023069887A1 (en) * | 2021-10-18 | 2023-04-27 | Yang, Kejian | Mucosal vaccine, methods of use and administration thereof |
CN114533754B (zh) * | 2022-02-23 | 2023-10-20 | 南京大学 | 一种广谱抗病毒纳米人工抗体及其制备方法和应用 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
DE3775783D1 (de) | 1986-01-14 | 1992-02-20 | Nederlanden Staat | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
FR2637324B1 (fr) | 1988-10-04 | 1994-02-25 | Peugeot Automobiles | Dispositif de commande de securite pour electropompe |
NL9002314A (nl) | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
ITMI981138A1 (it) | 1998-05-21 | 1999-11-21 | Getters Spa | Processo per la rimozione di acqua da camere evacuate o da gas |
EP2204186B1 (en) | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
EP2420247A1 (en) * | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
CN101428006A (zh) * | 2000-09-28 | 2009-05-13 | 诺华疫苗和诊断公司 | 微粒体组合物及其生产方法 |
IL155073A0 (en) | 2000-10-02 | 2003-10-31 | Glaxosmithkline Biolog Sa | Split enveloped virus preparation |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
CN1756562A (zh) * | 2003-03-07 | 2006-04-05 | 麦克公司 | 流感病毒疫苗 |
AU2004273776B2 (en) | 2003-04-25 | 2010-07-08 | Medimmune, Llc | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
WO2009012489A1 (en) | 2007-07-19 | 2009-01-22 | Novavax, Inc. | Avian influenza chimeric vlps |
WO2005080417A2 (en) | 2003-12-10 | 2005-09-01 | The Uab Research Foundation | Recombinant viruses with heterologous envelope proteins |
BRPI0517374A (pt) * | 2004-10-29 | 2008-10-07 | Harvard College | formulação para tratamento ou prevenção de infecção respiratória, método para tratamento |
US20070292386A9 (en) | 2004-12-02 | 2007-12-20 | Campbell Robert L | Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
ES2564241T3 (es) * | 2005-12-02 | 2016-03-21 | Glaxosmithkline Biologicals Sa | Nanopartículas para su uso en composiciones inmunogénicas |
AU2007242572B2 (en) * | 2006-04-13 | 2011-11-24 | Midatech Limited | Nanoparticles containing three various ligands for providing immune responses against infectious agents |
WO2007149490A1 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins |
EP2089515A4 (en) | 2006-11-16 | 2011-02-23 | Novavax Inc | VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS |
US8772256B2 (en) | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
CA2684578A1 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
US20100239671A1 (en) * | 2007-11-06 | 2010-09-23 | Edelman Elazer R | Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair |
EP2222710B8 (en) | 2007-12-24 | 2016-10-12 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
BRPI0908861A2 (pt) | 2008-02-25 | 2018-02-06 | Novavax Inc | partículas semelhantes a vírus de açucar vitrificado (vlps) |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
MX2011006205A (es) | 2008-12-09 | 2011-09-01 | Novavax Inc | Proteinas f del vrs modificadas y metodos de uso de las mismas. |
AU2010254550B2 (en) * | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
WO2011005183A1 (en) | 2009-07-10 | 2011-01-13 | Isconova Ab | New composition |
BR112012001666A2 (pt) | 2009-07-15 | 2019-09-24 | Novartis Ag | composições de proteína rsv f e métodos para fazer as mesmas |
AU2011235220B2 (en) | 2010-03-30 | 2016-03-10 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
CN107281478B (zh) | 2010-07-23 | 2022-04-01 | 诺瓦瓦克斯公司 | 流感疫苗 |
RS56157B1 (sr) * | 2010-11-05 | 2017-11-30 | Novavax Inc | Glikoproteinske čestice nalik virusu (vlp) besnila |
CN102107003A (zh) * | 2011-01-05 | 2011-06-29 | 重庆大学 | 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法 |
EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
RU2014117068A (ru) | 2011-09-30 | 2015-11-10 | Новавакс, Инк. | Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
SG11201506197TA (en) | 2013-02-11 | 2015-09-29 | Novavax Inc | Combination vaccine for respiratory syncytial virus and influenza |
KR102236497B1 (ko) * | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 rsv f 폴리펩타이드 |
CN105555306B (zh) * | 2013-09-19 | 2019-12-03 | 诺瓦瓦克斯股份有限公司 | 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法 |
AU2014100888A4 (en) | 2014-08-07 | 2014-09-11 | Novartis Ag | Virus clearance and protein purification methods |
IL257800B2 (en) | 2015-09-03 | 2023-11-01 | Novavax Inc | Immune compositions with improved stability and immunogenicity |
IL305911A (en) | 2018-03-19 | 2023-11-01 | Novavax Inc | Multifunctional nanoparticle vaccines for influenza |
-
2016
- 2016-09-06 IL IL257800A patent/IL257800B2/en unknown
- 2016-09-06 EP EP16843191.4A patent/EP3344291A4/en active Pending
- 2016-09-06 CN CN201680062822.XA patent/CN108697790B/zh active Active
- 2016-09-06 IL IL303336A patent/IL303336A/en unknown
- 2016-09-06 CN CN202210112637.4A patent/CN114699519A/zh active Pending
- 2016-09-06 SG SG10201913145SA patent/SG10201913145SA/en unknown
- 2016-09-06 US US15/257,436 patent/US10426829B2/en active Active
- 2016-09-06 BR BR112018004242A patent/BR112018004242A2/pt active Search and Examination
- 2016-09-06 CN CN202210102171.XA patent/CN114796474A/zh active Pending
- 2016-09-06 WO PCT/US2016/050413 patent/WO2017041100A2/en active Application Filing
- 2016-09-06 CA CA2996007A patent/CA2996007A1/en active Pending
- 2016-09-06 JP JP2018511471A patent/JP6670374B2/ja active Active
- 2016-09-06 RU RU2018111760A patent/RU2730625C2/ru active
- 2016-09-06 AU AU2016315478A patent/AU2016315478B2/en active Active
- 2016-09-06 MX MX2018002728A patent/MX2018002728A/es unknown
- 2016-09-06 CN CN202210076945.6A patent/CN114617959A/zh active Pending
- 2016-09-06 KR KR1020187009467A patent/KR20180052124A/ko active IP Right Grant
-
2017
- 2017-11-21 US US15/819,962 patent/US11364294B2/en active Active
-
2018
- 2018-03-02 MX MX2020011717A patent/MX2020011717A/es unknown
- 2018-03-02 MX MX2023000211A patent/MX2023000211A/es unknown
- 2018-04-27 JP JP2018087483A patent/JP6929819B2/ja active Active
- 2018-07-20 HK HK18109416.7A patent/HK1250136A1/zh unknown
-
2019
- 2019-08-20 US US16/545,424 patent/US11253585B2/en active Active
-
2021
- 2021-07-07 JP JP2021112811A patent/JP7461323B2/ja active Active
-
2022
- 2022-05-23 US US17/750,612 patent/US20220387579A1/en active Pending
-
2023
- 2023-10-13 AU AU2023248200A patent/AU2023248200A1/en active Pending
- 2023-12-27 JP JP2023221176A patent/JP2024038170A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
AR118725A2 (es) | Vectores para expresión de antígenos asociados a próstata | |
BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
BR112018008078A2 (pt) | vacina de vírus influenza de amplo espectro | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
BR112013022397A2 (pt) | vacinas combinadas com doses menores de antígeno e/ou adjuvante | |
CO6331297A2 (es) | Composiciones adyuvantes novedosas | |
CL2014002675A1 (es) | Composicion inmunogenica multivalente que comprende mycoplasma hyopneumaniae (m . hyo) y un antigeno del circovirus porcino del tipo 2 (pcv2); procedimiento para inmunizar; procedimiento para preparar la composicion. | |
BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
DK3570879T3 (da) | Immunogene sammensætninger til anvendelse i pneumokokvacciner | |
MX342716B (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
BR112022014830A2 (pt) | Formulações de vacina para coronavírus | |
AR102547A1 (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso | |
BR112015008417A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
CL2019000019A1 (es) | Anticuerpos con baja inmunogenicidad y uso de los mismos | |
UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
MX2022013912A (es) | Procedimientos novedosos para inducir una respuesta inmunitaria. | |
MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
BR112023019301A2 (pt) | Formulações de vacina de coronavírus | |
BR112014020025A8 (pt) | Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
BR112015020079A8 (pt) | Composições para cuidado oral | |
DK2938356T3 (da) | Immunogen sammensætning som omfatter mycoplasma-antigener | |
WO2012103444A3 (en) | Immunogenic compositions and reagents for preparing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |